GlassScriptPhysician profile
Merrick Brodsky
NPI 1609300649
$3,008.11
in general payments reported to CMS, 2019-2025
21 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 86% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2022: $133 · 2023: $197 · 2024: $822 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $800.40 | 2023-2025 | |
| Genzyme Corporation | $331.16 | 2024-2025 | |
| Ucb, INC. | $242.99 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $203.70 | 2024-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $165.11 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $163.21 | 2022-2025 | Dupixent |
| Leo Pharma INC. | $150.72 | 2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $143.21 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $123.20 | 2023-2025 | Taltz, Ebglyss, Zepbound |
| Amgen INC. | $107.16 | 2024 | Otezla |
| Allergan, INC. | $97.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $85.82 | 2024-2025 | Sotyktu |
| Incyte Corporation | $82.64 | 2024-2025 | Opzelura |
| Almirall LLC | $71.40 | 2024-2025 | Klisyri, Seysara |
| Sun Pharmaceutical Industries INC. | $62.76 | 2023-2025 | Blu-U |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $58.08 | 2025 | |
| Blueprint Medicines Corporation | $36.13 | 2025 | Ayvakit |
| Botanix Sb INC | $28.06 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $22.82 | 2024 | Ycanth |
| Pfizer INC. | $17.39 | 2024 | |
| Dermavant Sciences, INC. | $14.82 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merrick Brodsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.